AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate UpdatePhase 2 interim results suggest treatment with active ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...

Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout ...

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsJean-Paul Kress - Chairman ...

Spherix Global Insights today announces the release of its latest Market Dynamix(TM): Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable population of patients eligible for ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® ...